You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Gene Expression and Diagnosis of Autoimmune Disease

    SBC: ARTHROCHIP, LLC            Topic: N/A

    DESCRIPTION (provided by the applicant): Autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, type I diabetes, and multiple sclerosis, are thought to arise from abnormalities of innate or adaptive immune responses. Autoimmune diseases are often difficult to diagnose, as the symptoms can be typical of other conditions and quite vague, such as musculoskeletal complaints ...

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  2. Gene Expression and Diagnosis of Diabetes

    SBC: ARTHROCHIP, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Autoimmune diseases are difficult to diagnose, as the symptoms can be typical of other conditions and quite vague. No currently available blood test accurately excludes or includes the possibility of an autoimmune disease in a subject, and a battery of tests and a period of observation are usually required. A single test that could readily distinguish between ...

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  3. PPMP as a Ceramide Catabolism Inhibitor for Chemotherapy

    SBC: AVANTI POLAR LIPIDS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Our goal is to develop 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol (PPMP) as a clinical inhibitor of ceremide catabolism, in order to enhance the anti-cancer activity of the cytotoxic retinoid, fenretinide (4-HPR). We have reported that 4-HPR increased ceramide in numerous pediatric and adult solid cancer and leukemia cell lines in vitro. We have also ...

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  4. Prototype of Adjustable Systemic-Pulmonary Artery Shunt

    SBC: Cardiojustable, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): This proposal is to complete the feasibility prototype of an adjustable systemic-pulmonary artery (SPA) shunt. Children with single ventricle physiology (SVP) and reduced pulmonary blood flow (PBF) are palliated with an SPA shunt until approximately 6 months of age. Current shunts are made from simple (unadjustable) polytetrafluoroethylene (PTFE) vascular gr ...

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  5. Targeted Oncolytic VSV as a Prostate Cancer Therapy

    SBC: ONCTERNAL THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Prostate cancer is the most common malignancy in men in the United States and the second leading cause of cancer mortality. Unfortunately there is no cure by standard medical treatment. Therefore, novel treatments for this devastating, common disease are desperately needed. Recent progress in the development of targeted oncolytic viral vectors offer a new strat ...

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  6. Developing VSV cytolytics against High-Grade CNS gliomas

    SBC: ONCTERNAL THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Despite continued improvements in diagnosis, surgical techniques, and radiation protocols, the available treatments for high-grade malignant glioma are grossly inadequate. The median survival time for most patients with high-grade gliomas is on the order of months. Metastatic tumors with a tropism for the CNS such as lung and breast pose an even greater problem ...

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  7. Transgenic plant cells as source of hepatoprotective dr*

    SBC: NAPROGENIX, INC.            Topic: N/A

    Transgenic plant cells as source of hepatoprotective drugs. Alcoholic liver damage (ALD) is among the ten most common causes of death in the USA. The liver may be uniquely sensitive because it metabolizes ethanol at a high rate. This generates acetaldehyde intracellularly, damaging cell components directly, and/or inducing apoptotic cell death. Although some plant natural products are protective i ...

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  8. Single cycle reporter assay for quantifying HIV-1 Nab

    SBC: Tranzyme, Inc.            Topic: N/A

    N/A

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  9. Developing a novel adjuvant system for therapeutic vaccines against lung cancer

    SBC: FasCure Therapeutics LLC            Topic: 102

    DESCRIPTION provided by applicant Therapeutics is focused on the development of adjuvant systems with desired immune activities for targeted indications The Companyandapos s immune stimulatory adjuvant platform builds on combinatorial use of immune agonists with distinct immune targets and mechanisms of action for the generation of therapeutic immune responses Critical to this platform techno ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Target Identification for Novel Small Molecule Therapeutic for Alzheimer's disease

    SBC: CoPlex Therapeutics, LLC            Topic: NIA

    ABSTRACT Traditional approaches to drug development for Alzheimer s disease are becoming increasingly expensive and in many cases disappointingly unsuccessful Based on preliminary in vitro and in vivo studies we have identified a novel small molecule methyl dimethyl oxo dihydrobenzo c naphthyridine carboxylate UK that significantly decreases A production and pro in ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government